Ocular FC (Eye Disease Diagnostic System)

2023: Product Announcement

On November 29, 2023, medical technology company Zilia introduced the Ocular FC system, developed for non-invasive evaluation of ocular biomarkers. The complex is designed to detect ophthalmic diseases.

Ocular FC's platform is based on the principles of photonics and artificial intelligence. The complex uses the optical properties of the eyes and their direct connections with the vascular system and brain to obtain diagnostic information. According to Zilia, the implemented approach makes it possible to collect important indicators both about the state of the visual system and about the general state of health of the patient.

Founders of Zilia with new development - Ocular FC

The new technology involves imaging, spectrometry and AI tools to detect and measure biomarkers in the eye. The company says Ocular FC paves the way for further study of the body's metabolic responses as well as eye and brain pathophysiology. An important advantage of the platform is that it does not require any invasive intervention. Zilia has received approval for its complex from the U.S. Food and Drug Administration (FDA).

As of November 2023, Zilia emphasizes ocular oximetry: it is a monitoring method based on measuring the level of blood oxygen saturation, that is, on assessing the proportion of oxygenated hemoglobin relative to total hemoglobin in the blood. It is noted that oxygenation of the eyes is the most important biomarker of the main causes of vision loss, such as glaucoma, diabetic retinopathy and age-related macular degeneration.

This is a step forward in our quest to protect the eyesight of millions of people. The technology promises to revolutionize how we diagnose and treat various eye diseases, says Dr. Patrick Sauvageau, CEO and co-founder of Zilia.[1]

Notes